Business Context and Reporting Period
This Form 8-K filing by Minerva Neurosciences, Inc. (NERV) was submitted on April 12, 2024, reporting an event that occurred on April 10, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the Market Value of Listed Securities (MVLS), which has been below the minimum requirement of $35,000,000 for the last 31 consecutive business days.
Material Changes
The material change reported is the receipt of a formal notice from Nasdaq indicating noncompliance with Listing Rule 5550(b)(2) due to the MVLS falling below the $35,000,000 threshold. This represents a significant deviation from the continued listing standards required to maintain the Company's status on the Nasdaq Capital Market.
Outlook, Risks, and Contingencies
- Grace Period: The Company has been granted a 180-calendar-day grace period, ending on October 7, 2024, to regain compliance.
- Compliance Requirement: To maintain listing, the MVLS must close at $35,000,000 or more for a minimum of 10 consecutive business days within the grace period.
- Delisting Risk: If the Company fails to regain compliance by the deadline, it expects to receive notice that its securities are subject to delisting.
- Uncertainty: Management explicitly states there can be no assurance that the Company will be able to regain compliance with the MVLS standard or maintain other listing requirements.
Investor Verification Checklist
- Verify the current market capitalization and daily trading volume of NERV to assess the feasibility of meeting the $35,000,000 MVLS threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to track progress toward compliance.
- Review subsequent filings for any updates on capital raising activities or strategic initiatives intended to increase market value.
- Confirm the exact deadline of October 7, 2024, and watch for any potential extensions or further notices from Nasdaq.